Organization
Michael Hopp
1 clinical trial
Clinical trial
AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line SettingStatus: Active (not recruiting), Estimated PCD: 2024-06-30